SCHEMBL4522971

SCHEMBL4522971

CCOC(=O)c1ccc(NC(=O)c2n[nH]c3ccc(-c4cncc5ccccc45)cc23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 8/20 0.65
WNT1 P04628 6/20 0.65
RAB9A P51151 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
FLT3 P36888 6/20 0.53
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MMP9 P14780 1/20 0.48
DYRK3 O43781 1/20 0.47
MAP4K4 O95819 1/20 0.47
CDK1 P06493 1/20 0.47
CDK2 P24941 1/20 0.47
MARK3 P27448 1/20 0.47
CLK2 P49760 1/20 0.47
GSK3B P49841 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CSNK1G2 P78368 1/20 0.47
CDK5 Q00535 1/20 0.47
MAP4K2 Q12851 1/20 0.47
PRKAA1 Q13131 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523182 0.87 DYRK1A (0.67) DYRK1AWNT1FLT3MMP9DYRK3
SCHEMBL82655 0.84 DYRK1A (0.70) DYRK1AWNT1FLT3DYRK3MAP4K4
SCHEMBL6221286 0.81 CDK2 (0.65) DYRK1AWNT1FLT3DYRK3MAP4K4
SCHEMBL4531298 0.80 CDK2 (0.59) DYRK1AWNT1FLT3MMP9DYRK3
SCHEMBL953365 0.79 DYRK1A (0.61) DYRK1AWNT1FLT3DYRK3MAP4K4
SCHEMBL17096021 0.79 DYRK1A (1.00) DYRK1AWNT1CDK1CLK2GSK3B
Hydrochloric Acid SCHEMBL955121 0.78 DYRK1A (0.60) DYRK1AWNT1FLT3DYRK3MAP4K4
SCHEMBL4532307 0.77 TP53 (0.45) RAB9AL3MBTL1TP53SMN1; SMN2MMP9
SCHEMBL4523358 0.77 DYRK1A (0.58) DYRK1AWNT1CLK2
SCHEMBL6221471 0.77 DYRK1A (0.62) DYRK1AWNT1FLT3DYRK3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482342-B2 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors CDK2, CDK1, CDK4 DYRK1A 425/4885WNT1 364/4885RAB9A 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.